Sep 12, 2022 / 02:30PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Great. Well, good morning, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. pharma analyst at Morgan Stanley, and we're very pleased to be hosting Royalty Pharma today at our 20th Annual Global Healthcare Conference. Before we get started, I have to read some important disclosures. Please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Joining us today from the company, we have Pablo Legorreta, who is the Founder and CEO of Royalty; and Terry Coyne, who is Executive Vice President and CFO. Thank you both for joining me today.
I really appreciate it. And it's great to be back in person. Maybe Pablo to start, you could just share a little bit of background on the company. It is a more recent company for a number of investors given the IPO a couple of years ago. And it's definitely a
Royalty Pharma PLC at Morgan Stanley Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot